News – Page 1093 – Endpoints News

Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work

8 years ago

Axovant's lead Alzheimer's drug flops in PhIII, ending an unlikely quest

8 years ago

Two young scientists bag $20M to perfect their CRISPR attack on disease-causing bacteria at upstart Eligo

8 years ago

Genocea shelves its lead drug, slashes staff and switches focus to trendy neoantigens

8 years ago

ProQR spotlights the most encouraging results from a mixed snapshot of efficacy for cystic fibrosis

8 years ago

The top 5 trends in biotech - #3: High valuations for attractive biotechs are a durable symptom of a thriving ...

8 years ago

J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

8 years ago

Spark recruits gene therapy expert Mingozzi as new CSO; Fusion brings venture round to $46M; China OKs Gilead’s ...

8 years ago

Pfizer spins off drug orphans into a PhIII-ready startup backed by Bain to the tune of $103M

8 years ago

Puretech’s Gelesis flunks the FDA’s key measure of success for weight loss treatments

8 years ago

Visualize: What would these 11 biotech companies look like without immigrants?

8 years ago

Allergan caps a bad day with news the FDA has kicked back a supplemental application for cariprazine

8 years ago

FDA spurns J&J's troubled rheumatoid arthritis drug sirukumab

8 years ago

How Enterprise customers can get Endpoints News into their Slack

8 years ago

Publisher's note

AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

8 years ago

GSK vets Witty and Slaoui find new roles in biotech as the great migration continues

8 years ago

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

8 years ago

OrbiMed, RA Capital back a $26M raise for Realm’s two mid-stage drugs

8 years ago

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

8 years ago

House committee wants to know a lot more about the cyberattack that damaged Merck

8 years ago

Versartis shares hammered by a PhIII flop as growth hormone flunks key test

8 years ago

Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise

8 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

8 years ago

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

8 years ago

First page Previous page 1090 1091 109210931094 1095 1096 Next page Last page